Administration Guidance

Natroba™ (spinosad) can eradicate head lice infestations with a single, 10-minute application—no nit combing required. However, if live lice are seen seven days after the first treatment, a second treatment should be applied.

English

Watch a clinician demonstrate the proper application technique.

Properly Applying Natroba™

  • Use as much product as needed to completely cover the scalp first, and then apply outwards towards the ends of the hair.
  • For very thick, medium-length or long hair, an entire bottle (120 mL) of Natroba™ Topical Suspension may be needed to cover the scalp and hair. For shorter, thinner hair, less Natroba™ Topical Suspension may be needed.
  • If live lice are seen seven days after the first treatment, re-apply Natroba™.
Español

Un proceso tan fácil como 1-2-3 para aplicar la suspención tópica Natroba™ correctamente.

Pasos Importantes: Pon fin al ciclo del piojo

  • Cubra completamente el cuero cabelludo primero y luego aplique hacia afuera hacia las puntas del cabello. Es importante utilizar suficiente Natroba™ suspensión tópica para cubrir todo el cuero cabelludo y todo el cabello.
  • Para cabellos muy gruesos y de longitud media o cabellos largos, se puede necesitar una botella entera (120 ml) de Natroba™ para cubrir el cuero cabelludo y el cabello. Es posible que se necesite menos Natroba™ suspensión tópica para cabellos más cortos y finos.
  • Una semana (7 días) después de su primer tratamiento, si se ven piojos vivos, repita el tratamiento otra vez.

Important: For topical use only on scalp and scalp hair. Do not get Natroba™ Topical Suspension in eyes, mouth, or vagina.

Adjunctive measures

Natroba™ Topical Suspension should be used in the context of an overall lice management program:

  • Wash (in hot water) or dry clean all recently worn clothing, hats, used bedding and towels
  • Wash personal care items such as combs, brushes, and hair clips in hot water
  • A fine-toothed comb or special nit comb may be used to remove dead lice and nits.

Indication
Natroba™ Topical Suspension is a pediculicide indicated for the topical treatment of head lice infestations in patients six (6) months of age and older.

Adjunctive Measures
Natroba™ Topical Suspension should be used in the context of an overall lice management program:
• Wash (in hot water) or dry clean all recently worn clothing, hats, used bedding and towels
• Wash personal care items such as combs, brushes, and hair clips in hot water
• A fine-toothed comb or special nit comb may be used to remove dead lice and nits.

Important Safety Information
Natroba™ Topical Suspension contains benzyl alcohol and is not recommended for use in neonates and infants below the age of 6 months. Systemic exposure to benzyl alcohol has been associated with serious adverse reactions and death in neonates and low birth-weight infants when administered intravenously. Most common adverse events were: application site redness (3%), eye redness (2%) and application site irritation (1%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Reference(s)
  1. Natroba Prescribing Information

NAT-RRW11-002

Important Safety Information

Indication
Natroba™ Topical Suspension is a pediculicide indicated for the topical treatment of head lice infestations in patients six (6) months of age and older.

Adjunctive Measures
Natroba™ Topical Suspension should be used in the context of an overall lice management program:
• Wash (in hot water) or dry clean all recently worn clothing, hats, used bedding and towels
• Wash personal care items such as combs, brushes, and hair clips in hot water
• A fine-toothed comb or special nit comb may be used to remove dead lice and nits.

Important Safety Information
Natroba™ Topical Suspension contains benzyl alcohol and is not recommended for use in neonates and infants below the age of 6 months. Systemic exposure to benzyl alcohol has been associated with serious adverse reactions and death in neonates and low birth-weight infants when administered intravenously. Most common adverse events were: application site redness (3%), eye redness (2%) and application site irritation (1%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.